Microbial biotransformation offers access to selective oxidation, glycosylation, halogenation, methylation, amination, and other modifications of structurally complex plant natural products, yet catalytic possibility alone provides a poor basis for choosing useful transformations. A candidate reaction may be chemically plausible but fail because the relevant enzyme does not accept the scaffold, generates an unsuitable regioisomer or stereoisomer, performs differently in a microbial host, produces competing products, or creates an intermediate with little downstream value. This article develops an original, evidence-bounded biotransformation prioritization model that treats route selection as a conditional matching problem rather than a reaction-enumeration exercise. Four analytical dimensions are integrated: functional-group liability as a context-dependent transformation opportunity; enzyme-class capability tempered by substrate recognition and catalytic architecture; regio- and stereochemical outcome as independent determinants of product utility; and downstream value defined by diversification potential, pathway compatibility, recoverability, or production relevance. The analysis further separates isolated-enzyme feasibility from whole-cell feasibility and distinguishes catalytic success from route-level usefulness. Evidence from late-stage enzymatic modification, cytochrome P450 oxidation, glycosyltransferases, halogenases, methyltransferases, heterologous enzyme expression, microbial pathway reconstruction, transport engineering, and stereoselective biocatalysis is used to establish the constraints that a useful prioritization framework must respect. The resulting model is proposed as a qualitative decision architecture, not a validated predictive score. Its principal limitation is the scarcity of systematically reported negative transformations and prospective cross-enzyme benchmarks needed to estimate generalizable success probabilities.
